GlassScriptPhysician profile
Pitcha Chompoopong
NPI 1629420542
$11,613.53
in general payments reported to CMS, 2019-2025
9 companies · $7,146 in 2025
The $7,146 reported for 2025 was more than what 76% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $70.51 · 2024: $4,262 · 2025: $7,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,565 · Travel and Lodging: $2,032 · Consulting Fee: $1,611 · Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,565.00 |
| Travel and Lodging | $2,032.35 |
| Consulting Fee | $1,611.00 |
| Food and Beverage | $199.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $9,696.79 | 2024-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $1,711.00 | 2024-2025 | Wainua |
| Genentech USA, INC. | $71.67 | 2019-2020 | |
| Csl Behring | $50.06 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $27.77 | 2020 | |
| Genzyme Corporation | $16.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.54 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pitcha Chompoopong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.